Byetta Safety Concerns Could Set Roadblocks Ahead For New GLP-1s
This article was originally published in The Pink Sheet Daily
Executive Summary
Amylin/Lilly’s Byetta LAR and Novo Nordisk’s liraglutide could face tougher regulatory scrutiny after cases of pancreatitis are linked to exenatide.